Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pyxis Oncology (PYXS) EBT (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed EBT for 2 consecutive years, with -$17.0 million as the latest value for Q4 2025.

  • Quarterly EBT rose 54.94% to -$17.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$78.8 million through Dec 2025, up 3.47% year-over-year, with the annual reading at -$78.2 million for FY2025, 1.59% up from the prior year.
  • EBT for Q4 2025 was -$17.0 million at Pyxis Oncology, up from -$22.0 million in the prior quarter.
  • The five-year high for EBT was -$5.3 million in Q1 2024, with the low at -$37.7 million in Q4 2024.